4.7 Article

Predictive Factors, Management, and Clinical Outcomes of Coronary Obstruction Following Transcatheter Aortic Valve Implantation Insights From a Large Multicenter Registry

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 62, Issue 17, Pages 1552-1562

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.07.040

Keywords

coronary obstruction; coronary occlusion; percutaneous aortic valve replacement; percutaneous coronary intervention; transcatheter aortic valve implantation

Funding

  1. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brasil
  2. Edwards Lifesciences
  3. St. Jude Medical
  4. Medtronic
  5. Abbott
  6. Capricor
  7. CardioKinetix
  8. Venus Medtech
  9. Direct Flow Medical
  10. Instituto de Salud Carlos III (Madrid, Spain)

Ask authors/readers for more resources

Objectives This study sought to evaluate the main baseline and procedural characteristics, management, and clinical outcomes of patients from a large cohort of patients undergoing transcatheter aortic valve implantation (TAVI) who suffered coronary obstruction (CO). Background Very little data exist on CO following TAVI. Methods This multicenter registry included 44 patients who suffered symptomatic CO following TAVI of 6,688 patients (0.66%). Pre-TAVI computed tomography data was available in 28 CO patients and in a control group of 345 patients (comparisons were performed including all patients and a cohort matched 1: 1 by age, sex, previous coronary artery bypass graft, transcatheter valve type, and size). Results Baseline and procedural variables associated with CO were older age (p<0.001), female sex (p<0.001), no previous coronary artery bypass graft (p = 0.043), the use of a balloon-expandable valve (p = 0.023), and previous surgical aortic bioprosthesis (p = 0.045). The left coronary artery was the most commonly involved (88.6%). The mean left coronary artery ostia height and sinus of Valsalva diameters were lower inpatients with obstruction than in control subjects (10.6 +/- 2.1 mm vs. 13.4 +/- 2.1 mm, p<0.001; 28.1 +/- 3.8 mm vs. 31.9 +/- 4.1 mm, p<0.001). Differences between groups remained significant after the case-matched analysis (p < 0.001 for coronary height; p = 0.01 for sinus of Valsalva diameter). Most patients presented with persistent severe hypotension (68.2%) and electrocardiographic changes (56.8%). Percutaneous coronary intervention was attempted in 75% of the cases and was successful in 81.8%. Thirty-day mortality was 40.9%. After a median follow-up of 12 (2 to 18) months, the cumulative mortality rate was 45.5%, and there were no cases of stent thrombosis or reintervention. Conclusions Symptomatic CO following TAVI was a rare but life-threatening complication that occurred more frequently in women, in patients receiving a balloon-expandable valve, and in those with a previous surgical bioprosthesis. Lower-lying coronary ostium and shallow sinus of Valsalva were associated anatomic factors, and despite successful treatment, acute and late mortality remained very high, highlighting the importance of anticipating and preventing the occurrence of this complication. (C) 2013 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available